These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11336571)

  • 1. Current use of biologicals for the treatment of spondyloarthropathies.
    Keyser FD; Mielants H; Veys EM
    Expert Opin Pharmacother; 2001 Jan; 2(1):85-93. PubMed ID: 11336571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut inflammation and spondyloarthropathies.
    De Keyser F; Baeten D; Van den Bosch F; De Vos M; Cuvelier C; Mielants H; Veys E
    Curr Rheumatol Rep; 2002 Dec; 4(6):525-32. PubMed ID: 12427369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF-alpha therapy in ankylosing spondylitis.
    De Keyser F; Van den Bosch F; Mielants H
    Cytokine; 2006 Mar; 33(5):294-8. PubMed ID: 16516484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Spondylarthropathies and anti-TNFalpha drugs].
    Pavy S; Allanore Y; Kahan A
    Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Reddig J; Sieper J; Braun J
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
    Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
    Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].
    Wendling D; Claudepierre P; Lohse A; Toussirot E; Breban M
    Presse Med; 2003 Oct; 32(32):1517-24. PubMed ID: 14534471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Verbruggen G; Mielants H; Veys E
    Drugs; 2004; 64(24):2793-811. PubMed ID: 15563249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides.
    Homeff G; Burgos-Vargas R
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S137-42. PubMed ID: 12463465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
    Baeten D; Kruithof E; Van den Bosch F; Van den Bossche N; Herssens A; Mielants H; De Keyser F; Veys EM
    Ann Rheum Dis; 2003 Sep; 62(9):829-34. PubMed ID: 12922954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy.
    Schnarr S; Kuipers JG; Zeidler H
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S126-9. PubMed ID: 12463462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
    Braun J; de Keyser F; Brandt J; Mielants H; Sieper J; Veys E
    Curr Opin Rheumatol; 2001 Jul; 13(4):245-9. PubMed ID: 11555723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the armamentarium for the spondyloarthropathies.
    Peloso PM; Braun J
    Arthritis Res Ther; 2004; 6 Suppl 2(Suppl 2):S36-43. PubMed ID: 15228620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.